Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YBL-006 in Advanced Solid Tumors
NCT04450901Phase 2Unknown
- Sponsor
- Y-Biologics
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of acrixolimab in solid tumor (advanced stage) (8 cohorts), sponsored by Y-Biologics. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events, Incidence of Treatment-Emergent Adverse Events through Vital Signs and 2 more. Status: unknown.
02
Drugs
acrixolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04450901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450901.